Suggested remit - To appraise the clinical and cost effectiveness of cannabidiol within its marketing authorisation for adjuvant treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome.
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
1211
|
Provisional Schedule
| Expected publication |
18 December 2019 |
Project Team
| Project lead |
Jeremy Powell |
Email enquiries
| Evidence Review Group / Assessment Group |
Kleijnen Systematic Reviews |
Consultees
| Companies sponsors |
GW Pharma |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Dravet Syndrome UK |
| |
Epilepsy Action |
| |
Epilepsy Society |
| Professional groups |
Association of British Neurologists |
| |
Primary Care and Community Neurology Society |
| |
Royal College of Physicians |
Commentators
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
Accord Healthcare (clobazam, topiramate) (not participating) |
| |
Atnahs Pharma UK (clobazam) (not participating) |
| |
Aurobindo Pharma - Milpharm (topiramate) (not participating) |
| |
Biocodex (stiripentol) (not participating) |
| |
Desitin Pharma (sodium valproate) (not participating) |
| |
Janssen (topiramate) (not participating) |
| |
Martindale Pharma (clobazam) (not participating) |
| |
Mylan (topiramate) (not participating) |
| |
Rosemont Pharmaceuticals (clobazam) (not participating) |
| |
Sandoz (topiramate) (not participating) |
| |
Sanofi (clobazam, sodium valproate) (not participating) |
| |
Thame Laboratories (clobazam) (not participating) |
| |
Wockhardt UK (sodium valproate) (not participating) |
| |
Zentiva (sodium valproate) (not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Epilepsy Group |
|
Date
|
Update
|
|
11 November 2019 - 27 November 2019
|
Final appraisal document |
|
29 October 2019
|
Committee meeting: 3 |
|
26 September 2019
|
Committee meeting: 2 |
|
23 August 2019 - 16 September 2019
|
Appraisal consultation: 1 |
|
30 July 2019
|
Committee meeting: 1 |
|
14 March 2019
|
The date of the first Committee meeting has been amended to 30 July 2019. |
|
31 October 2018
|
Invitation to participate |
|
24 April 2018
|
In progress, referral |
|
16 January 2018 (10:00)
|
Scoping workshop (London) |
|
21 November 2017 - 19 December 2017
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance